Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis.
Endeavor BioMedicines has raised $132.5M in total funding. The most recent round was Series C. The last funding was announced in April 2024.
Endeavor BioMedicines's investors include Perceptive Advisors, Omega Funds, Fidelity, Ally Bridge Group, Avidity Partners.
Endeavor BioMedicines is headquartered in Solana Beach, United States.
Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis.
Endeavor BioMedicines is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Endeavor BioMedicines — Funding & Investors." VCBacked, April 24, 2024, https://www.vcbacked.co/company/endeavor-biomedicines. Accessed November 12, 2026.
VCBacked. (2024). Endeavor BioMedicines — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/endeavor-biomedicines
{{cite web |title=Endeavor BioMedicines — Funding & Investors |url=https://www.vcbacked.co/company/endeavor-biomedicines |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Endeavor BioMedicines? Request a listing update